Joseph Schlessinger, PhD
William H. Prusoff Professor and Chair of Pharmacology, Department of Pharmacology, Yale School of Medicine, New Haven, Connecticut
A leader in oncology research, Dr. Schlessinger is renowned for his work in the field of receptor tyrosine kinases (RTKs) and for elucidating their intracellular signaling pathways. Dr. Schlessinger discovered that RTKs such as the epidermal growth factor receptor (EGFR) form dimers upon binding of their extracellular ligands. He demonstrated that once these proteins dimerize, they become activated, autophosphorylate, and subsequently induce their downstream, intracellular signaling pathways. This principle has proved to be fundamental to activation of the majority of surface receptors and for information flow from the cell surface into intracellular compartments. He demonstrated that protein-protein interactions through SH2 and SH3 domains and other small protein modules are essential for regulation of signal transduction activity. He discovered the SH2/SH3 adaptor protein Grb2 and showed that Grb2 links activated EGFR with Ras signaling. Dr. Schlessinger's discovery that activated EGFR facilitates the assembly of signaling molecules serves as a prototype for interactions between different protein modules crucial for the control of every aspect of signal transduction. He used biochemical, genetic and structural approaches to elucidate the mechanism of RTK activation at atomic resolution and demonstrated that dysfunction of these receptors causes various human cancers, such as those driven by mutations or amplification of the EGF receptor gene. These pioneering studies provided the conceptual foundation for developing a new class of targeted cancer therapies directed against kinases, leading to the discovery of many successful cancer drugs. To date more than 20 kinase inhibitors have been approved for clinical use. These drugs have become front-line cancer therapies and are the harbinger of other rationally targeted cancer therapies, including sunitinib and vemurafenib, two drugs discovered in companies Dr. Schlessinger founded.
2014 BBVA Foundation Frontiers of Knowledge Award2010 Pezcoller Foundation-AACR International Award for Cancer Research2009 Order of Danica Hrvatska Medal, Republic of Croatia2008 Elected Foreign Member, Croatian Academy of Science2006 Dan David Prize, Dan David Foundation, Tel Aviv University2006 Elected Foreign Member, Russian Academy of Sciences2004 Elected Member, Institute of Medicine2004 Elected Member, European Academy of Sciences2001 Elected Fellow, American Academy of Arts and Sciences2000 Elected Member, National Academy of Sciences, Washington, DC2000 J. Allyn Taylor International Prize in Medicine1995 Ciba-Drew Award in Biomedical Research1995 Antoine Lacassagne Prize1984 Levinson Prize1974 PhD, Weizmann Institute of Science, Israel